Overview

• Gilead reported adjusted Q1 earnings per share of $1.81, surpassing analyst expectations of $1.79, while revenue remained flat at $6.7 billion, slightly below forecasts.
• HIV drug Biktarvy saw a 7% sales increase to $3.15 billion, and liver disease drug sales rose 3% to $758 million, offsetting declines in other segments.
• Oncology drug Trodelvy sales dropped 5% to $293 million, missing estimates, while COVID antiviral Veklury sales fell 45% to $302 million due to reduced hospitalization rates.
• The company reaffirmed its 2025 full-year guidance, projecting adjusted EPS of $7.70–$8.10 and product sales of $28.2–$28.6 billion despite external challenges like tariffs.
• A key regulatory decision on Gilead's twice-yearly HIV prevention injection, lenacapavir, is anticipated from the FDA by June 19, which could significantly impact growth.